Post-relapse treatment of CD30 expressing lymphomas
US8758758B1 · kind B1 · utility
7Cited by
1References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 6, 2011 |
| Grant date | Jun 24, 2014 |
| Priority date | — |
| Expiry date | Aug 20, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for the retreatment of CD30-expressing lymphomas with an anti-CD30 vc-PAB-MMAE antibody-drug conjugate are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.